Finn
RDY Pharmaceuticals · Generics · India · Biosimilars · Thesis updated October 25, 2026

Semaglutide fixes clear the path for a critical catalyst year

01 Running thesis

A fragile bridge after Revlimid

Dr. Reddy's is managing a difficult transition. Generic Revlimid was a major profit source, but its January 2026 patent cliff is actively cutting into North American revenue. The company needs new growth drivers to fill that gap.

The bull case relies on consumer health additions in Europe and complex generic launches. The integration of the acquired nicotine replacement therapy business is largely complete and driving strong European growth. Furthermore, the company has resolved its semaglutide active ingredient scale-up issues and expects to resume supply by November 2026.

The bear case centers on execution risk for upcoming catalysts. The Abatacept biosimilar has a crucial December 2026 FDA goal date. Approval requires a final establishment inspection report for the Bachupally facility, which received a Form 483 with seven observations in June 2026.

Finn's view is balanced. The valuation is favorable, and the recent resolution of semaglutide issues improves the outlook. However, the company remains in a vulnerable transition period until the Abatacept decision is final.

Oct 2026▲Q2 FY2027 earnings confirmed that semaglutide API issues were resolved with a target to resume supply in November 2026. The company also secured FDA approval for its rituximab biosimilar.
Jul 2026▼Q1 FY2027 earnings revealed execution stumbles on major catalysts. Canadian semaglutide sales were halted due to API challenges, and the Bachupally biologics facility received a Form 483 with seven observations.
May 2026→Q4 confirmed that semaglutide is approved in Canada and India, and that Abatacept IV was accepted by the FDA for review. The thesis improves on execution, but stays balanced because Revlimid pressure and semaglutide pricing risk are now live.
Jan 2026▲Dr. Reddy's completed the Abatacept IV BLA filing in December 2025, as planned. That reduced a key timeline risk, even as the Revlimid cliff began to hit North America.
Oct 2025→Q2 showed Europe growing fast from the NRT deal while North America kept sliding on Revlimid. Management also added a U.S. CMO for Abatacept, which helps reduce launch and tariff risk.
Jul 2025▼Q1 showed clear Revlimid price erosion in North America and a Form 483 with 7 observations at Srikakulam FTO 11. Europe growth helped, but the risk mix worsened.
May 2025→The starting thesis centered on whether Dr. Reddy's could bridge the January 2026 Revlimid cliff. Management pointed to consumer health, semaglutide, Abatacept, and biosimilars as the main bridge pieces.
02 Business model

Generics cash, harder launches

Dr. Reddy's makes money by selling generic medicines around the world. It also sells active pharmaceutical ingredients and does some contract manufacturing work for other drug companies.

The traditional model leaned on broad generic scale, especially in North America. The newer strategy shifts toward higher-value areas like consumer health, complex generics, innovative products in emerging markets, and biosimilars. This shift is designed to offset normal generic price decay and sudden patent cliffs.

Management wants double-digit sales growth and about 25 percent EBITDA margins over time. They have also identified a 500 to 600 basis point discretionary cost lever in sales and research spending if margins need defense during the transition.

This model breaks if new launches arrive late, price too low, or fail regulatory inspection. It also struggles if the base U.S. generic business erodes faster than Europe, India, and emerging markets can grow.

03 Product portfolio

What fills the medicine cabinet

Cash cow

Global generics

This is the core business of producing copies of branded drugs. North America remains important, but it is under heavy pressure from Revlimid price erosion.

Cash cow

Lenalidomide

Generic Revlimid has been a major contributor, but the patent cliff is now active and reducing North American sales.

Growth engine

Nicotine replacement therapy

The acquired consumer health business in Europe is largely integrated and driving triple-digit regional growth year-over-year.

Growth engine

Semaglutide

Approved in 10 countries. The company resolved recent manufacturing challenges and plans to resume supply by November 2026.

Option

Abatacept biosimilar

The intravenous version has a December 2026 FDA goal date. Approval relies heavily on clearing regulatory observations at the Bachupally facility.

Option

Rituximab biosimilar

Recently secured U.S. FDA approval. It will be commercialized in the U.S. through a partnership with Fresenius Kabi.

Steady

India brands

India is growing double digits, helped by new launches, volume, and selected brand acquisitions like Stugeron.

04 Business segments

Where sales come from

North America Generics37%declining
Emerging Markets20%growing fast
India18%growing fast
Europe15%growing fast
PSAI and other10%declining

The mix reflects general historical trends outlined by management, where North America is the largest segment but also the most exposed to Revlimid declines.

05 Risk factors

What can still break

Biosimilar approval delays

High impact · High odds

The Bachupally biologics facility received a Form 483 with seven observations in June 2026. The company is awaiting the final establishment inspection report, which threatens the December 2026 FDA goal date for Abatacept.

We watchFDA inspection classifications for Bachupally and the final Abatacept decision.

Semaglutide final validation

High impact · Medium odds

While the active ingredient scale-up issues are resolved, the company still requires successful final validation of the drug product before resuming sales in November 2026.

We watchUpdates on semaglutide final validation and the timeline for resuming shipments.

Revlimid cliff cuts deeper

High impact · High odds

The January 2026 Revlimid cliff is actively dragging down North America revenue. If the base U.S. business does not stabilize, margin pressure will persist during the transition.

We watchNorth America generic revenue excluding lenalidomide.

India semaglutide IP loss

Medium impact · Medium odds

Dr. Reddy's launched semaglutide in India, but the company is challenging patents in the Delhi High Court. A bad ruling could limit sales or change launch economics in a key early market.

We watchDelhi High Court rulings or settlement terms related to semaglutide patents.

Tariff pressure

Medium impact · Medium odds

Potential U.S. generic or active ingredient tariffs could hurt supply chains and margins. Using a U.S. contract manufacturer for Abatacept helps, but it does not remove the risk for the broader generic portfolio.

We watchNew U.S. tariff policy covering pharmaceutical generics or active ingredients.
06 Quick answers

In one breath

What does Dr. Reddy's Laboratories do?

Dr. Reddy's sells generic medicines, active pharmaceutical ingredients, consumer health products, and biosimilars. Its main markets include North America, Europe, India, and emerging markets.

Why does Revlimid matter so much for RDY?

Revlimid is the branded drug name for lenalidomide, and Dr. Reddy's generic version was a major profit source. The patent cliff began in January 2026, causing more competition and lower prices in North America.

Is semaglutide already approved for Dr. Reddy's?

Yes, it is approved in 10 countries including Canada and India. After resolving a manufacturing challenge, the company aims to resume supply in November 2026.

What is the next big catalyst for RDY?

The key upcoming catalysts are the targeted November 2026 resumption of semaglutide supply and the December 22, 2026 FDA goal date for the Abatacept biosimilar.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
October 25, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Dr. Reddy's FY2027 Q2 earnings transcript, October 23, 2026
  2. Dr. Reddy's FY2027 Q1 earnings transcript, July 22, 2026
  3. Dr. Reddy's FY2026 Q4 earnings transcript, May 12, 2026
  4. Dr. Reddy's FY2026 20-F filing, May 29, 2026
08 Explore the industry

Comparable Drug Manufacturers - Specialty & Generic companies

Companies near Dr. Reddy's Laboratories Limited in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

Get started with Finn today